{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:28:43Z","timestamp":1791336523274,"version":"4.3.1"},"reference-count":64,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Platinum drugs are major chemotherapeutic agents that are used alone or in combination with other systemic agents and\/or radiation therapy in the management of many human malignancies. All three platinum drugs approved by the Food and Drug Administration, cisplatin, carboplatin, and oxaliplatin, are administrated intravenously. Satraplatin is the first orally administered platinum drug under active clinical investigation. Satraplatin and its major metabolite, JM118, have shown antineoplastic activity in in vitro, in vivo, and in clinical settings. Use of satraplatin as an alternative platinum cytotoxic agent is particularly attractive because of the convenience of administration, milder toxicity profile, lack of cross-resistance with cisplatin, theoretical advantage as a radiosensitizer, and activity in cancers historically nonresponsive to platinum drugs. The most mature clinical data for satraplatin come from the recently completed phase III trial that investigated the efficacy of satraplatin and prednisone on hormone-refractory prostate cancer patients who had failed a course of other chemotherapy agents. Preliminary reports show that the combination is statistically superior to placebo and prednisone in multiple end points, including progression-free survival, prostate-specific antigen response, objective tumor response, pain response, and duration of pain response. The difference in overall survival, however, did not reach statistical significance.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-07-2176","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T19:27:59Z","timestamp":1205782079000},"page":"1633-1638","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":199,"title":["Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue"],"prefix":"10.1158","volume":"14","author":[{"given":"Hak","family":"Choy","sequence":"first","affiliation":[{"name":"Authors' Affiliation: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Park","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yao","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,3,17]]},"reference":[{"key":"2022061105501880900_bib1","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome inhibitors in cancer therapy: lessons from the first decade","volume":"14","author":"Orlowski","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061105501880900_bib2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-07-2179","article-title":"Aurora kinases as anticancer drug targets","volume":"14","author":"Gautschi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061105501880900_bib3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1158\/1078-0432.CCR-07-2201","article-title":"The epothilones: translating from the laboratory to the clinic","volume":"14","author":"Lee","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061105501880900_bib4","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1158\/1078-0432.CCR-07-2219","article-title":"Vinflunine: a new microtubule inhibitor agent","volume":"14","author":"Bennouna","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061105501880900_bib5","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1078-0432.CCR-07-2249","article-title":"Newer cytotoxic agents: attacking cancer broadly","volume":"14","author":"Teicher","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061105501880900_bib6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1517\/13543784.9.6.1373","article-title":"An update on satraplatin: the first orally available platinum anticancer drug","volume":"9","author":"Kelland","year":"2000","journal-title":"Exp Opin Investig Drugs"},{"key":"2022061105501880900_bib7","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/bjc.1996.656","article-title":"The cytotoxic action of four ammine\/amine platinum(IV) dicarboxylates: a flow cytometric study","volume":"74","author":"Ormerod","year":"1996","journal-title":"British journal of cancer"},{"key":"2022061105501880900_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ijc.2910620612","article-title":"DNA-binding properties of novel cis and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines","volume":"62","author":"Mellish","year":"1995","journal-title":"International journal of cancer"},{"key":"2022061105501880900_bib9","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1021\/ja00040a026","article-title":"DNA binding properties of cis-[Pt(NH3)(C6H11NH2)Cl2], a metabolite of an orally active platinum anticancer drug","volume":"114","author":"Hartwig","year":"1992","journal-title":"J Am Chem Soc"},{"key":"2022061105501880900_bib10","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/sj.bjc.6694381","article-title":"Gene-specific repair of Pt\/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin","volume":"81","author":"O'Neill","year":"1999","journal-title":"British journal of cancer"},{"key":"2022061105501880900_bib11","first-page":"3968","article-title":"Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts","volume":"59","author":"Reardon","year":"1999","journal-title":"Cancer research"},{"key":"2022061105501880900_bib12","first-page":"4881","article-title":"The role of DNA mismatch repair in platinum drug resistance","volume":"56","author":"Fink","year":"1996","journal-title":"Cancer research"},{"key":"2022061105501880900_bib13","doi-asserted-by":"crossref","first-page":"11026","DOI":"10.1021\/bi9909187","article-title":"Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts","volume":"38","author":"Vaisman","year":"1999","journal-title":"Biochemistry"},{"key":"2022061105501880900_bib14","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0006-2952(02)00983-8","article-title":"JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin","volume":"63","author":"Fokkema","year":"2002","journal-title":"Biochemical pharmacology"},{"key":"2022061105501880900_bib15","author":"Wosikowksi"},{"key":"2022061105501880900_bib16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00280-007-0502-z","article-title":"Preclinical antitumor activity of the oral platinum analog satraplatin","volume":"60","author":"Wosikowski","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061105501880900_bib17","first-page":"2581","article-title":"Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug","volume":"53","author":"Kelland","year":"1993","journal-title":"Cancer research"},{"key":"2022061105501880900_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0009-2797(99)00115-5","article-title":"Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells","volume":"123","author":"O'Neill","year":"1999","journal-title":"Chem Biol Inter"},{"key":"2022061105501880900_bib19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/bjc.1993.322","article-title":"In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin","volume":"68","author":"Mellish","year":"1993","journal-title":"Br J Cancer"},{"key":"2022061105501880900_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bcp.2006.06.008","article-title":"Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells","volume":"72","author":"Martelli","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"2022061105501880900_bib21","first-page":"5674","article-title":"Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin","volume":"52","author":"Twentyman","year":"1992","journal-title":"Cancer Res"},{"key":"2022061105501880900_bib22","author":"Wosikowski"},{"key":"2022061105501880900_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00001813-200602000-00012","article-title":"Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts","volume":"17","author":"Sova","year":"2006","journal-title":"Anticancer drugs"},{"key":"2022061105501880900_bib24","first-page":"14620","article-title":"Satraplatin, an oral platinum analog, is active and synergistic with paclitaxel and docetaxel in prostate carcinoma models","volume":"24","author":"Lamphere","year":"2006","journal-title":"J Clin Oncol Meeting Abstracts"},{"key":"2022061105501880900_bib25","author":"Obermayr"},{"key":"2022061105501880900_bib26"},{"key":"2022061105501880900_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(06)70619-X","article-title":"Synergistic interaction between erlotinib and JM118, the active metabolite of satraplatin","author":"Peters","year":"2006","journal-title":"Eur J Cancer"},{"key":"2022061105501880900_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s002800050624","article-title":"Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models","volume":"40","author":"Rose","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061105501880900_bib29","author":"Obermayr"},{"key":"2022061105501880900_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s002800000169","article-title":"Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy","volume":"46","author":"Amorino","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061105501880900_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002800050464","article-title":"Biotransformation of the platinum drug JM216 following oral administration to cancer patients","volume":"38","author":"Raynaud","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061105501880900_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0021-9673(95)00288-X","article-title":"Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry","volume":"712","author":"Poon","year":"1995","journal-title":"J Chromatograph"},{"key":"2022061105501880900_bib33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685793","article-title":"A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration","volume":"36","author":"McKeage","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061105501880900_bib34","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.1997.15.7.2691","article-title":"Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer","volume":"15","author":"McKeage","year":"1997","journal-title":"J Clin Oncol"},{"key":"2022061105501880900_bib35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jjco\/hyd102","article-title":"Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study","volume":"30","author":"Kurata","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"2022061105501880900_bib36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1023\/A:1008441416790","article-title":"Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days","volume":"9","author":"Sessa","year":"1998","journal-title":"Ann Oncol"},{"key":"2022061105501880900_bib37","first-page":"2757","article-title":"Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days","volume":"23","author":"Vouillamoz-Lorenz","year":"2003","journal-title":"Anticancer Res"},{"key":"2022061105501880900_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s002800050797","article-title":"Phase I study of oral JM216 given twice daily","volume":"42","author":"Beale","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061105501880900_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/PL00006749","article-title":"Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients","volume":"45","author":"Fokkema","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061105501880900_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s002800050911","article-title":"A phase I study of oral uracil\/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days","volume":"43","author":"DeMario","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061105501880900_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1014473930546","article-title":"Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies","volume":"20","author":"Jones","year":"2002","journal-title":"Invest New Drugs"},{"key":"2022061105501880900_bib42","first-page":"393a","article-title":"Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer [abst 1520]","volume":"18","author":"Cmelak","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2022061105501880900_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1023\/A:1010653508700","article-title":"A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest","volume":"19","author":"George","year":"2001","journal-title":"Invest New Drugs"},{"key":"2022061105501880900_bib44","first-page":"488a","article-title":"Oral JM-216 plus concomitant radiotherapy (RT) for patients (PTS) with advanced malignancies of the chest [abstract 1878]","volume":"17","author":"Hoffman","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2022061105501880900_bib45"},{"key":"2022061105501880900_bib46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G","article-title":"Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer","volume":"71","author":"Yagoda","year":"1993","journal-title":"Cancer"},{"key":"2022061105501880900_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cncr.22439","article-title":"Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer","volume":"109","author":"Oh","year":"2007","journal-title":"Cancer"},{"key":"2022061105501880900_bib48","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061105501880900_bib49","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061105501880900_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/B:DRUG.0000047109.76766.84","article-title":"Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)","volume":"23","author":"Latif","year":"2005","journal-title":"Invest New Drugs"},{"key":"2022061105501880900_bib51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000084201","article-title":"Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer","volume":"68","author":"Sternberg","year":"2005","journal-title":"Oncology"},{"key":"2022061105501880900_bib52","author":"Petrylak"},{"key":"2022061105501880900_bib53","doi-asserted-by":"crossref","first-page":"abstract 5019","DOI":"10.1200\/jco.2007.25.18_suppl.5019","article-title":"Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial","volume":"25","author":"Sternberg","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2022061105501880900_bib54","unstructured":"Available from: http:\/\/www.prostate-cancer.org\/advocacy\/SatraplatinFDA_Review.html. Accessed Jan 7, 2008."},{"key":"2022061105501880900_bib55","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.1999.17.12.3822","article-title":"Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer","volume":"17","author":"Fokkema","year":"1999","journal-title":"J Clin Oncol"},{"key":"2022061105501880900_bib56","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1023\/A:1008245709924","article-title":"Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation","volume":"8","author":"Judson","year":"1997","journal-title":"Ann Oncol"},{"key":"2022061105501880900_bib57","first-page":"Abstract 1858","article-title":"Randomized phase II study of oral JM216 versus intravenous (iv) cisplatin in non-small cell lung cancer (NSCLC): preliminary results","author":"Fokkema","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2022061105501880900_bib58"},{"key":"2022061105501880900_bib59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/gyno.2001.6409","article-title":"A phase II trial of JM-216 in cervical cancer: an NCIC CTG study","volume":"84","author":"Trudeau","year":"2002","journal-title":"Gynecol Oncol"},{"key":"2022061105501880900_bib60","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199202203260805","article-title":"Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer","volume":"326","author":"Schaake-Koning","year":"1992","journal-title":"N Engl J Med"},{"key":"2022061105501880900_bib61","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ijrobp.2005.01.003","article-title":"The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer","volume":"62","author":"Schild","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022061105501880900_bib62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.coc.0000145986.78542.44","article-title":"Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer","volume":"28","author":"Keene","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"2022061105501880900_bib63","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00000421-200206000-00015","article-title":"Phase II trial of continuous infusion carboplatin, 5-fluorouracil, and radiotherapy for localized cancer of the esophagus","volume":"25","author":"Jefford","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"2022061105501880900_bib64","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2004.10.076","article-title":"Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck","volume":"22","author":"Jeremic","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/14\/6\/1633\/1980329\/1633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/14\/6\/1633\/1980329\/1633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T21:10:56Z","timestamp":1654981856000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/14\/6\/1633\/196500\/Current-Status-and-Future-Prospects-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,15]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,3,17]]},"published-print":{"date-parts":[[2008,3,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-2176","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,15]]}}}